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Dear Editor,
A 74-year-old woman was diagnosed with multiple
myeloma type IgG kappa, Salmon and Durie stage III A
in August 2004. Haemoglobin was 108 g/l, IgG 90.3 g/l,
and calcium was normal. Bone marrow infiltration was 40–
50%. She received chemotherapy with cyclophosphamide
and prednisone from September 04 to July 05 and reached a
partial remission. Upon progression in February 06, she
was treated with high-dose dexamethasone until July 06
and had another partial remission. From June 07 to October
07, she was treated with bortezomib and dexamethasone
which resulted in a near complete remission. In June 08, CT
scan revealed enlargement of the right thyroid lobe (8.6×
5.3 cm). Cytology showed plasma cells, compatible with
extramedullary myeloma. IgG remained normal. She
received radiotherapy to the right cervical region (50 Gy).
During radiotherapy, M-protein was increasing. CT scan
performed 2 weeks after the end of radiotherapy showed an
unchanged right thyroid lobe. Four weeks later, thalidomide
and dexamethasone were started. After three cycles, a
serological and morphological complete remission was
obtained. Treatment was stopped in December 08. In
March 09, a small monoclonal peak in the serum protein
electrophoresis was detected. In May 09, CT scan performed
because of persistent cough with minor haemoptysis revealed
a large mediastinal mass (6.4×5.1×4.0 cm). Bronchial biopsy
showed plasma cells infiltrating the mucosa compatible
with extramedullary myeloma. Lenalidomide, high-dose
dexamethasone and radiotherapy to the mediastinum
(30 Gy) were started concomitantly and resulted in another
complete remission (Fig. 1). Therapy with lenalidomide and
low-dose dexamethasone is currently ongoing.
Extramedullary (EM) manifestations of multiple myeloma
can occur at primary diagnosis, during the disease or as
solitary EM plasmocytoma without bone marrow involve-
ment [1]. A longitudinal study on extramedullary disease on
1,003 consecutive myeloma patients showed a rising
incidence of EM in the last decades, from 4% in the period
1971–93 to 12% between 2000 and 2007 [2]. This trend has
been attributed to more sensitive imaging techniques and
prolonged patients' survival. There is no correlation between
high-dose chemotherapy or the use of novel agents and the
increased incidence of EM disease [2]. EM manifestations of
multiple myeloma indicate poor prognosis [3]. Patients with
EM disease during follow-up had lower levels of serum
M-protein and haemoglobin and increased lactate dehydro-
genase (LDH), compared to patients with EM disease at
diagnosis [2]. Our patient had, at both EM relapses, normal
haemoglobin and LDH; M-protein was low.
EM myeloma is frequently treated with radiotherapy
despite its role is not well defined in this setting. Forty-four
percent of patients with EM disease during follow-up
received radiation therapy [2]. There is no consensus on
the effect of thalidomide on extramedullary manifestations
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DOI 10.1007/s00277-010-0946-9of MM [4–6]. Reports indicate low response rates of EM
disease to thalidomide. Our patient had recurrent EM
relapses at two different rarely involved sites, she showed
excellent responses to both currently available IMiDs and
has long survival of 21 months after first EM relapse. This
is in contrast to a recently reported patient with extra-
medullary disease in the thyroid and the pericardium at
presentation who did not respond to any treatment [7].
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Fig. 1 CT-scans before and
after therapy (see text)
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